Choline, a hydrophilic cation, has versatile physiological roles throughout the body, including cholinergic neurotransmission, memory consolidation and membrane biosynthesis and metabolism. Choline kinases possess enzyme activity that catalyses the conversion of choline to phosphocholine, which is further converted to cytidine diphosphate-coline (CDP-choline) in the biosynthesis of phosphatidylcholine (PC). PC is a major constituent of the phospholipid bilayer which constitutes the eukaryotic cell membrane, and regulates cell signal transduction. Choline
Introduction
Choline, a charged hydrophilic cation, plays an important role in various organs and cells throughout the body, including cholinergic neurotransmission, memory consolidation and as a critical component of cell membranes. Choline is an essential nutrient and can be produced within the body through the degradation of choline containing phospholipids; however, this source is insufficient to maintain choline levels and dietary intake of choline is necessary to prevent cholinedeficiency associated liver and muscle damage [1] . Within cells choline is predominantly incorporated as phosphatidylcholine, which is a crucial component of the cell membrane and has secondary roles as a substrate to produce lipid second messengers including phosphatidic acid and diacylglycerol [1] .
Choline uptake is a key step in biosynthetic pathways utilising choline (Fig. 1) , and is controlled by the activities of non-specific transporters (organic cation transporters; OCT), and high and low affinity choline specific transporters (choline transporter, CHT1; choline transporter like, CTL1) [2] .
Following uptake into cells, choline is converted to acetylcholine through the actions of Choline acetyltransferase (ChAT), which is required for cholinergic neurotransmission [3] , and failures in this process have been implicated in Alzheimer's disease, brain ischemic events, and aging [2, 4] .
As stated above, the principle choline processing pathway in cells is the generation of phosphatidylcholine. In this pathway choline is initially synthesised into phosphocholine through the actions of choline kinase [5] . Phosphocholine is further converted to cytidine diphosphatecholine (also known as citicoline, cytidine 5'-diphosphocholine, or CDP-choline) and subsequently to phosphatidylcholine [1] (Fig. 1 ). Within this pathway phosphocholine has recently been shown to have functions independent of its role as an intermediate in phosphatidylcholine synthesis [5] , and as such the role of Choline Kinase and subsequent phosphocholine production has become of great interest.
Choline Kinase has three isoforms: CHKα1, CHKα2 and CHKβ which are encoded by CHKA(Human)/Chka(Mouse) and CHKB(Human)/Chkb(Mouse) genes respectively and was discovered since early 1950, but its biological roles in muscular dystrophy, bone deformities, and cancer have only recently been described [6] . This review discusses recent progresses on the molecular structure and expression pattern of Choline Kinase, the differential roles of Choline Kinase isoforms in muscular dystrophy, bone deformities, cognitive conditions and cancer, as well as the potential as novel therapeutic targets for these disorders.
Molecular structure of Choline Kinase: CHKα and CHKβ
Choline Kinase exists in at least 3 isoforms; CHKα1 and CHKα2 are produced by alternate splicing of the CHKA(Human)/Chka(Mouse) gene, whereas CHKβ (also called Chetk, Chkl) is separately encoded by CHKB(Human)/Chkb(Mouse) [7] . Sequence alignment shows that mice CHKα1 shares 48.47% sequence identity with CHKβ with 222 amino acids in identical positions ( Fig. 2A) and a similar result has also been seen for human CHKα1 and CHKβ isoforms, with human and mouse orthologues sharing greater than 85% sequence similarity. Although CHKβ carries an additional Nacetylalanine site at the N-terminal region, all Choline Kinase proteins share a similar functional region containing one substrate binding site, two nucleotide binding sites, three ATP binding sites (Fig. 2B) as well as some analogous potential ligands (Magnesium, ADP, Kanamycin). Moreover, multiple structure rigid-body alignment (Fig. 3) showed a distinct RMSD (The Root-MeanStandard-Deviation) score (2.906 Å) between CHKα and CHKβ, indicating a lower, but still noticeable, degree of similarity, which was further displayed in detail through 3D protein structure analysis (Fig. 4) . Functional Choline Kinase exists as a dimer, and can form homodimers or heterodimers with differential dynamics dependent on the tissue type [8] . CHKα homodimers display higher enzymatic activity than CHKβ homodimers and CHKα/β heterodimers [5] with tissues differing in their relative expression of the varying isoforms. BIOGPS analysis reveals that CHKA(Human)/Chka(Mouse) and CHKB(Human)/Chkb(Mouse) genes have both common and differential expression patterns in cells and tissues (Fig. 5) , which CHK has highest expression in testis interstitial cells and lowest expression among whole blood, while CHKβ expresses strongly in
CD14
+ monocytes but only marginally in ciliary ganglion and atrioventricular node, indicative of their shared and distinct biological functions. These expression patterns are important for the tissue specific function of CHKα and CHKβ in both physiological and pathological stages.
Although we now have summarised some mutual characteristics between CHK and CHKβ and further explored their considerable differences on the basis of their gene expression, sequence alignments, three-dimensional tertiary structures, potential cavities and pockets as well as preexisting studies, etc, we still barely know the connections between the gene expression and their unique biological functions, the discrepant efficiency caused by homodimers or heterodimers and how do those active sites and speculated ligands contribute to their enzymatic functions. We believe that a clearer picture and a more thorough analysis of the molecular structures shall be required for narrowing down those knowledge gaps and thus leading us to drug discoveries.
The Biological Functions of Choline Kinase: CHKα and CHKβ

The role of CHKα
Mice lacking the Chka gene die at an early stage of embryogenesis, pointing to an important role in organ development [9] . Evidence suggests that the phosphocholine produced by the actions of CHKα is an important second messenger in DNA synthesis, hence the essential role of this enzyme during development [10] . CHKα has also been extensively implicated in human tumorigenesis.
CHKα1 positively regulates cell proliferation and survival via activation of PI3K/AKT and MAPK signalling pathways [11] . Its overexpression has been detected in 40-60% of human tumours [12] , and high levels of CHKα correlate with poor prognosis [13] . Overexpression of the CHKα protein can transform noncancerous cells into cells with a cancerous phenotype, and conversely, knockdown of the CHKα protein by siRNA can result in cancer cell death [14] . It has also been shown that siRNA mediated knockdown of CHKA results in upregulation of autophagy, which was further associated with a reduction in cell proliferation in breast cancer cell lines [15] . The precise molecular mechanism underlying this link between choline metabolism and autophagy is unclear.
It has been demonstrated that CHKα activity can be induced by collaborative signalling between the epidermal growth factor receptor (EGFR) and c-Src in breast cancer cells. Evidence suggests a direct interaction between EGFR and CHKα protein, modulated by c-Src phosphorylation [16] . It has been proposed that CHKα is acting as a scaffold in this interaction, and its function is independent of its kinase activity [17] . This was supported by the evidence that inhibition of CHKα catalytic activity using the compound V-11-0711 reduced cellular phosphocholine levels but did not affect cancer cell survival as long as concentrations of CHKα protein were unaffected [17] . At higher concentrations causing reductions in CHKα and phosphatidylcholine, V-11-0711 resulted in a reversible cell growth arrest [14] . Further, CHKα can act as an androgen receptor (AR) chaperone in prostate cancer, suggesting a role of CHKα for AR associated tumour progression [18] .
Given its involvement in cancer development, CHKα has been proposed as a diagnostic biomarker for cancer by immunohistochemistry [19] and facilitated the development of radiolabels for positron emission tomography (PET) imaging as well as pharmacodynamic markers for non-invasive magnetic resonance spectroscopy (MRS), since the enzymatic changes of choline transporters, such as CHKα, will give rise to a raise in total choline (tCho) signal which can be detected by (1)H magnetic resonance spectroscopy [20] . Furthermore, real time quantitative PCR has also been employed as a prognostic tool for determination of CHKα1 expression levels in nonsmall cell lung cancer [13] and, besides, there are several other reviews that have also been wellcovered in the latest information of CHKα relating to tumor metabolism and the diagnosis [21, 22] .
Collectively, CHKα has emerged as a promising molecular target for cancer diagnosis and treatment.
The role of CHKβ
A recessive mouse mutation resulting in a 1.6-kb intragenic deletion within the Chkb gene was found to cause loss of CHKβ activity and was associated with rostrocaudal muscular dystrophy and neonatal forelimb bone deformities in mouse [23] . The muscular dystrophy in the skeletal muscle increased in severity from rostral to caudal tissues [23] . The loss of CHKβ resulted in impaired phosphatidylcholine biosynthesis, accompanied by an accumulation of choline and increased phosphatidylcholine catabolism [6, 24] . Mitochondria within the skeletal muscle were found to be abnormally large, concomitant with decreased membrane potential [24] . The enlarged mitochondria are potentially due to compensation for defective mitochondria in Chkb mutant cells [24] . The impaired phospholipid metabolism in the mitochondria-associated inner membrane was correlated with the abnormal size and aberrant cellular localisation of muscle mitochondria [25] .
A genome-wide association study in humans using 500K SNP microarrays suggest that a genetic variant with decreased Chkb expression is associated with narcolepsy [26] . Chkb mutations that cause megaconial congenital muscular dystrophy (MCMD) have been found in many human cases from Japanese, Turkish, and British populations. Affected muscle cells from individuals exhibit characteristics of mitochondrial enlargement at the periphery of muscle fibres, concomitant with the loss of mitochondria in the centre of muscle fibres [27] . In addition, several patients with Chkb mutations with MCMD showed mitochondrial mitophagy in muscle cells [28] . Interestingly, several patients have been described with mutations in Chkb resulting in loss of components of the mitochondrial electron transport chain [29, 30] . These studies indicate that mutation of Chkb in mice and humans presents a similar phenotype within the muscle cells, indicating conservation of CHKβ function between species.
Involvement of CHKβ in bone and cartilage homeostasis
Recent studies have found that CHKβ has a critical role in the normal embryogenic formation of the radius and ulna in mice. Chkb -/-mice display expanded hypertrophic zones in the radius and ulna with disrupted proliferative columns in their growth plates, accompanied by delayed formation of primary ossification centers and impaired chondrocyte differentiation [31] .
Interestingly these chondrocyte defects appear to be constrained to the forelimb bones during embryogenesis, indicative of a pattern-specific mode of regulation. We further identified CHKβ as a novel regulator of bone homeostasis in adult mice throughout the entire axial skeleton [32] . In our study N-ethyl-N-nitrosourea (ENU) mutagenesis was employed to generate a repertoire of mutants for gene function studies [33] . Phenotypic screening identified a mouse line exhibiting a bone loss phenotype with forelimb bone deformities. The affected locus was identified as the Chkb gene through sequencing; an A->T single base substitution in the first codon resulted in no detectable CHKβ protein product in affected mice [32] . Chkb mutant mice showed elevated osteoclast numbers and activity [32] . The biosynthesis of phosphatidylcholine was impaired in osteoclasts from Chkb mutant mice with reduced levels of phosphocholine and CDP-choline [32] .
The reduced phosphocholine levels also impacted osteoblast mineralising activity. In line with this finding, mineralisation requires the activity of the phosphatase PHOSPHO1 [34] , whose predominant substrate is phosphocholine [35] . The combined enhancement of osteoclast formation and function, and reduction in osteoblast activity result in the observed osteoporosis in the Chkb mutant mouse line [32] .
The underpinning molecular mechanism by which CHKβ impacts bone homeostasis is not clear.
As mentioned above, the loss of phosphocholine directly impacts osteoclast resorptive function; however, the exact role of CHKβ in osteoclasts remains to be elucidated. Osteoclastic bone resorption is regulated by RANKL/RANK and down-stream signaling processes; including the formation of F-actin rings mediated by c-src, activation of V-ATPase via coupling with chloride channel [36, 37] , and stimulation of calcium influx via calcium channels [38] . RANK activation results in phosphorylation of PI3K [39] , which has been shown to regulate the activation of CHKβ [40] . Interestingly, recent microarray analysis showed that choline kinase is able to regulate the gene expression of both chloride channels and voltage-dependent calcium channels [10] . In the light of these findings, it is possible that the activation of RANK/PI3K/CKβ might regulate osteoclastic bone resorption via regulating the gene expression of chloride and voltage-dependent calcium channels essential for osteoclast function [36, 37] . Thus, it will be important to define RANK/PI3K/CHKβ downstream targets that are involved in osteoclastic bone resorption.
Understanding the role of CHKβ in bone loss may lead to the discovery of a new molecular target for anti-resorptive drug development.
Therapeutic targets of Choline Kinase: CHKα and CHKβ
Compound inhibitors of Choline Kinase
CHKα is overexpressed in various human tumours and has become a key drug or gene target for MN58b is a well characterized CHKα inhibitor [12] . CHKα protein expression was directly correlated with sensitivity to MN58b, which caused endoplasmic reticulum stress and ultimately resulted in the induction of apoptosis [41] . Consistently, knockdown of Chka resulted in resistance to MN58B induced cell death. In addition, gemcitabine-resistant pancreatic ductal
adenocarcinoma (PDAC) cells displayed enhanced sensitivity to CHKα inhibition and, in vitro,
MN58b had additive or synergistic effects with gemcitabine, 5-fluorouracil, and oxaliplatin, in the treatment of pancreatic ductal adenocarcinoma [42] .
Hemicholinium-3 (HC-3), also known as hemicholine can block the reuptake of choline by the high-affinity choline transporter and decreases the synthesis of acetylcholine [43] . HC-3 is also known as an inhibitor of Choline Kinase. The inhibitory actions of HC-3 are likely owing to one of HC-3 oxazinium rings complexed with CHKα1 and occupied the choline-binding pocket [44] . The inhibitory effects of HC-3 are much more profound on CHKα than on CHK, suggesting a specificity of action that could be useful for differential targeting of the Choline Kinase isoforms in human cancer.
novel selective inhibitor against CHKα was found to inhibit CHKα activity, reduce the steady-state concentration of phosphocholine in transformed cells, and selectively suppress the growth of neoplastic cells [45] . Further, CK37 was found to attenuate tumour growth via Ras-AKT/ERK signalling in a T-lymphoma xenograft murine model [46] .
Compound V-11-0711 is a novel selective inhibitor of CHKα that can act at low doses to selectively reduce phosphocholine levels without impacting CHKα protein levels and phosphatidylcholine concentrations [17] . As opposed to other Choline Kinase inhibitors, V-11-0711
does not target the choline binding pocket of Choline Kinase, but selectively interacts with the catalytic domain of CHKα. Furthermore, V-11-0711 displays an 11-fold higher specificity for CHKα over CHKβ, hence this compound might represent a novel potential selective CHKα inhibitor [14] .
Other small molecule inhibitors to CHKα are also currently being validated for their antioncogenic properties [47] . Despite the extensive evidence suggesting an important role for CHKα in promoting tumour formation, CHKβ has not been implicated in this process. Given the similarity of CHKα and CHKβ and the functional activity of homo or heterodimers the design of anti-tumor drugs selectively targeting the CHKα isoform is challenging. Blockade of CHKβ activity might lead to detrimental changes to mitochondrial function and lipid content alteration in muscle cells.
Ideally, the novel selective CHKα inhibitors will have high specificity and efficiency with limited side effects due to undesirable actions on CHKβ in host cells.
Supplemental therapies to target Choline Kinase deficiency using CDP-choline
Deletion of choline kinase genes leads to abnormal phosphatidylcholine biosynthesis and catabolism. Using various experimental animal models, long term administration of CDP-choline to aged mice was shown to elicit a partial recovery of dopamine and acetylcholine receptor densities and function in the striatum of mice [48] , and to mitigate memory impairment resulting from poor environmental conditions in rats [49] . More recently, CDP-choline supplementation was found to improve regeneration and functional restoration of injured sciatic nerves and nerve adherence and separability in rats [50, 51] , and to exert neuroprotective effects via stimulating axonal regeneration in peripheral nerve injury in rat [52] . In addition, CDP-choline supplements may be used as a potential therapeutic agent to prevent necrotizing enterocolitis [53] , and bronchopulmonary dysplasia in rats [54] .
Notably, human studies have shown that CDP-choline (also known as citicoline -an international non-proprietary name) supplements might be beneficial in patients with mild mental deterioration and Alzheimer's disease with APOE genotype [55] , and also in patients with non-arteritic ischaemic optic neuropathy [56] . CDP-choline supplements might also be used as a pro-cognitive strategy [57] , and evidence is suggestive for a role in cognitive enhancement through a nicotinic cholinergic mechanism in healthy volunteers [58] . Randomized clinical CDP-choline trials have shown improved outcome of ischemic and hemorrhagic clinical stroke [59] . However, more recent clinical trials have revealed no benefits in ischaemic stroke and traumatic brain injury [60] . The efficacy of CDP-choline in the treatment of neural pathologies remains to be further investigated, however it has an excellent biosafety profile [59] .
Given the recent discovery of a predominant role for CHKβ in the musculoskeletal system, supplementation with CDP-choline, a regimen that bypasses CHKβ deficiency, might be particularly useful to treat CHKβ deficiency in musculoskeletal conditions. Indeed, it has been shown that CDPcholine can elicit a repairing effect on the damaged membranes of aged animals [61] . Injection of CDP-choline was able to increase the phosphatidylcholine content of hindlimb muscles and partially rescued the muscle weakness in Chkb mutant mice [24] . A recent study revealed that a human patient with a Chkb mutation with loss of function also had changes in mitochondria in their cardiac muscle [62] . For patients such as these CDP-choline supplements might be beneficial to reduce the need for heart transplant. Changes in phosphatidylcholine levels in cardiac muscle have been correlated with aberrations in mitochondrial function and subsequently increased risk for heart disease [63] , and modification of phosphatidylcholine synthesis pathways via treatment with CDP-choline shows potential as a novel treatment approach for cardiomyocyte dysfunction [64] .
Osteoporotic fracture is a highly significant problem as it results in much morbidity and mortality, of particular concern is that osteoporotic fractures in the elderly have been correlated with increased mortality rates [65, 66] . The identification of a role for CHKβ in the skeletal system could pave the way for the development of a novel therapeutic regime for this highly widespread medical condition. In Chkb mutant mice, treatment with CDP-choline in vivo and in vitro was able to restore abnormal osteoclast numbers to physiological levels, indicating that CDP-choline supplements might also be beneficial against osteoporosis [32] .
Conclusion
The functions of Choline Kinase in the production of phosphatidylcholine have been known for nearly 70 years, however we still do not completely understand the mechanisms by which the cell specific activities of this kinase are controlled. The three isoforms of Choline Kinase, CHK1, CHK2 and CHK, share similar structures and enzyme activity, but display some distinct molecular structural domains and differential tissue expression patterns. The importance of CHKα in human cancer development and progression together with the emerging understanding of the importance of CHKβ in musculoskeletal tissues, and the potential to specifically target these molecules in pathological processes will support significant further research into these essential kinases.
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